Disc Medicine, Inc. (IRON)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 30.77 |
| Open | 30.85 |
| Bid | 30.31 x 100 |
| Ask | 30.48 x 100 |
| Day's range | 29.48 - 31.25 |
| 52-week range | 25.60 - 77.60 |
| Volume | |
| Avg. volume | 488,608 |
| Market cap | 750.551M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings date | 09 Aug 2024 - 13 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 57.44 |
- GuruFocus.com
Disc Medicine Inc (IRON) Reports Q1 2024 Earnings: A Detailed Financial Overview
Aligns Closely With Analyst Projections Amidst Strategic Clinical Advancements
GlobeNewswireDisc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and AURORA in Q2 2024Plan to present updated data from the phase 1b/2 study of DISC-0974 in anemia of myelofibrosis (MF), as well as initial single-ascending dose (SAD) data from the phase 1 study of DISC-3405 in healthy volunteers in Q2 2024Continue to be well-capitalized, ending Q1 2024 with $343M in cash
ZacksBiotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
Disc Medicine, Inc. (IRON) and Verve Therapeutics (VERV) fall on study updates.
© 2024 Yahoo. All rights reserved.